Vesatolimod

Vesatolimod
Identifiers
	IUPAC name 4-amino-2-butoxy-8-{[3-(pyrrolidin-1-ylmethyl)phenyl]methyl}-5,7-dihydropteridin-6-one;
CAS Number	1228585-88-3;
PubChem CID	46241268;
DrugBank	DB12687;
ChemSpider	27289075;
UNII	O8M467C50G;
KEGG	D11003;
ChEMBL	ChEMBL2424780;
CompTox Dashboard (EPA)	DTXSID40153741 ;
Chemical and physical data
Formula	C22H30N6O2
Molar mass	410.522 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCOC1=NC(=C2C(=N1)N(CC(=O)N2)CC3=CC=CC(=C3)CN4CCCC4)N;
	InChI InChI=1S/C22H30N6O2/c1-2-3-11-30-22-25-20(23)19-21(26-22)28(15-18(29)24-19)14-17-8-6-7-16(12-17)13-27-9-4-5-10-27/h6-8,12H,2-5,9-11,13-15H2,1H3,(H,24,29)(H2,23,25,26); Key:VFOKSTCIRGDTBR-UHFFFAOYSA-N;

Vesatolimod (GS-9620) is an antiviral drug developed by Gilead Sciences, which acts as a potent and selective agonist of Toll-like receptor 7 (TLR7), a receptor involved in the regulation of the immune system. It is used to stimulate the immune system, which can increase its ability to combat chronic viral infections. Vesatolimod is in clinical trials to determine whether it is safe and effective in patients with Hepatitis B and HIV/AIDS,^[1]^[2] and has also shown activity against other viral diseases such as norovirus and enterovirus 71.^[3]^[4]

References

^ Janssen HL, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, et al. (March 2018). "Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B". Journal of Hepatology. 68 (3): 431–440. doi:10.1016/j.jhep.2017.10.027. PMID 29104121.
^ Riddler SA, Para M, Benson CA, Mills A, Ramgopal M, DeJesus E, et al. (October 2020). "Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults with HIV-1". Clinical Infectious Diseases. 72 (11): e815–e824. doi:10.1093/cid/ciaa1534. PMID 33043969.
^ Enosi Tuipulotu D, Netzler NE, Lun JH, Mackenzie JM, White PA (May 2018). "TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation". Antimicrobial Agents and Chemotherapy. 62 (5). doi:10.1128/AAC.02417-17. PMC 5923118. PMID 29530841.
^ Zhang Q, Zhao B, Chen X, Song N, Wu J, Li G, et al. (May 2018). "GS-9620 inhibits enterovirus 71 replication mainly through the NF-κB and PI3K-AKT signaling pathways". Antiviral Research. 153: 39–48. doi:10.1016/j.antiviral.2018.02.002. PMID 29425831. S2CID 4703478.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Janssen HL, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, et al. (March 2018). "Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B". Journal of Hepatology. 68 (3): 431–440. doi:10.1016/j.jhep.2017.10.027. PMID 29104121.

[2] Riddler SA, Para M, Benson CA, Mills A, Ramgopal M, DeJesus E, et al. (October 2020). "Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults with HIV-1". Clinical Infectious Diseases. 72 (11): e815–e824. doi:10.1093/cid/ciaa1534. PMID 33043969.

[3] Enosi Tuipulotu D, Netzler NE, Lun JH, Mackenzie JM, White PA (May 2018). "TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation". Antimicrobial Agents and Chemotherapy. 62 (5). doi:10.1128/AAC.02417-17. PMC 5923118. PMID 29530841.

[4] Zhang Q, Zhao B, Chen X, Song N, Wu J, Li G, et al. (May 2018). "GS-9620 inhibits enterovirus 71 replication mainly through the NF-κB and PI3K-AKT signaling pathways". Antiviral Research. 153: 39–48. doi:10.1016/j.antiviral.2018.02.002. PMID 29425831. S2CID 4703478.

[1]

[2]

[3]

[4]

See also

References